1 active not recruiting, 1 completed, 1 withdrawn. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow IRX-2: new trials by email Literature Review of IRX-2 trials Research Report on IRX-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer Cyclophosphamide, IRX-2, Nivolumab - Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Phase 1 | Withdrawn | Emory University | 2020-07-01 | 2019-08-28 | |
| IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Nivolumab - Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 8 | 2019-05-17 | 2026-08-21 |
| IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Pembrolizumab - Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 9 | 2019-04-30 | 2026-10-21 |
Carcinoma, Hepatocellular (1) · Squamous Cell Carcinoma of Head and Neck (1)
City of Hope Medical Center (2) · Emory University (1)
United States (3)
Daneng Li (1) · Joseph Chao (1) · Mihir Patel, MD (1)
P30CA033572 (1)